Somatostatin imaging of neuroendocrine-differentiated prostate cancer.
Clin Nucl Med
; 40(6): 540-1, 2015 Jun.
Article
em En
| MEDLINE
| ID: mdl-25783510
ABSTRACT
After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases. Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using In-labeled octreotide.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Radioisótopos de Índio
/
Octreotida
/
Adenocarcinoma
/
Tumores Neuroendócrinos
/
Compostos Radiofarmacêuticos
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article